Take a look back at this week's top stories.
By Hindi Stohl, MD, JD, James M. Shwayder, MD, JD
This month's Legally Speaking column delves into a case regarding shoulder and abdominal dystocia during a vaginal delivery for fetal hydrops.
By Lindsey Carr, Editor
Alabama’s attorney general retracted comments he made last week suggesting criminal prosecution for women taking abortion pills for pregnancy termination. He is now saying that only providers who prescribe the pills could be prosecuted.
By Lindsey Carr, Editor
If approved, DARE-HRT1 would become the first FDA-approved monthly intravaginal ring to deliver both estrogen and progestin hormone therapy.
By Lindsey Carr, Editor
Findings from a study in JAMA Network Open reveal valuable insight into the way cannabis legalization has impacted the perceptions of pregnant women who use cannabis in the US.
By Lindsey Carr, Editor
A new study in Menopause found body dissatisfaction to be a primary cause of eating disorders, especially during perimenopause.
By John Jesitus
Women on Medicaid with opioid use disorder (OUD) who use medications for opioid use disorder (MOUD) are more likely to use contraception and to undergo female sterilization than peers not prescribed MOUD, according to a study in Contraception.
By Lindsey Carr, Editor
The findings indicate a previously confirmed notion that COVID-19 vaccination does not impact pregnancy outcomes in couples experiencing infertility.
See you next week!
Single iron infusion in late pregnancy significantly reduces anemia risk
January 22nd 2025A recent study found that a single dose of intravenous iron in the third trimester is superior to oral iron in reducing anemia rates in pregnant women, ensuring better outcomes for mother and baby.
Read More
FDA grants 510(k) clearance to cobas liat STI multiplex assay panels
Published: January 22nd 2025 | Updated: January 22nd 2025The new panels, leveraging rapid polymerase chain reaction technology, allow point of care sexually transmitted infection diagnosis in 20 minutes, enhancing targeted treatment and reducing follow-up losses.
Read More